Cargando…

Short-duration dynamic [(18)F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [(18)F]DCFPyL PET/MR at 120 minutes

PURPOSE: Localized prostate cancer (PCa) in patients is characterized by a dominant focus in the gland (dominant intraprostatic lesion, DIL). Accurate DIL identification may enable more accurate diagnosis and therapy through more precise targeting of biopsy, radiotherapy and focal ablative therapies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Dae-Myoung, Alfano, Ryan, Bauman, Glenn, Thiessen, Jonathan D., Chin, Joseph, Pautler, Stephen, Moussa, Madeleine, Gomez, Jose A., Rachinsky, Irina, Gaed, Mena, Chung, Kevin J., Ward, Aaron, Lee, Ting-Yim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519985/ https://www.ncbi.nlm.nih.gov/pubmed/34652551 http://dx.doi.org/10.1186/s13550-021-00844-0

Ejemplares similares

Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [(18)F]DCFPyL-PET: comparison to [(18)F]fluorocholine-PET
por: Yang, Dae-Myoung, et al.
Publicado: (2021)

Cylindroma, an uncommon presentation on (18)F-DCFPyL PET/CT
por: Koene, B. P. F., et al.
Publicado: (2020)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
por: Pan, Ke-Hao, et al.
Publicado: (2021)

The differential diagnostic value of dual-phase (18)F-DCFPyL PET/CT in prostate carcinoma
por: Tian, Aijuan, et al.
Publicado: (2022)

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of (18)F-DCFPyL PET/CT Restaging
por: Liu, Wei, et al.
Publicado: (2020)

Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
por: Roy, Jyoti, et al.
Publicado: (2021)

Clinical verification of (18)F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
por: Meijer, Dennie, et al.
Publicado: (2020)

(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
por: Mesci, Aruz, et al.
Publicado: (2023)

(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
por: Zhou, Shuoming, et al.
Publicado: (2022)

Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
por: Wondergem, M., et al.
Publicado: (2019)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Uptake of [(18)F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies
por: Rowe, Steven P., et al.
Publicado: (2015)

Non-prostate cancer tumours: incidence on (18)F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients
por: Perry, Elisa, et al.
Publicado: (2022)

(18)F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
por: Metser, Ur, et al.
Publicado: (2022)

The diagnostic performance of (18)F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis
por: Pang, Wenyang, et al.
Publicado: (2023)

Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models
por: Bouvet, Vincent, et al.
Publicado: (2016)

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia
por: Werner, Rudolf A., et al.
Publicado: (2017)

Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution
por: Ferreira, Gonçalo, et al.
Publicado: (2019)

Uptake of prostate-specific membrane antigen-targeted (18)F-DCFPyL in avascular necrosis of the femoral head
por: Torga, Gonzalo, et al.
Publicado: (2019)

Uptake of prostate-specific membrane antigen-targeted (18)F-DCFPyL in avascular necrosis of the femoral head
por: Safali, Selim, et al.
Publicado: (2020)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

PSA-Stratified Performance of [(18)F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy
por: Harsini, Sara, et al.
Publicado: (2022)

Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023)

A Pilot Study of (18)F-DCFPyL PET/CT or PET/MRI and Ultrasound Fusion Targeted Prostate Biopsy for Intra-Prostatic PET-Positive Lesions
por: Liu, Yachao, et al.
Publicado: (2021)

Pathological predictors of (18)F‐DCFPyL prostate‐specific membrane antigen‐positive recurrence after radical prostatectomy
por: Perry, Elisa, et al.
Publicado: (2022)

Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018)

(18)F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center
por: Metser, Ur, et al.
Publicado: (2021)

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis
por: Sun, Jiale, et al.
Publicado: (2021)

The Impact of (18)F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

[(18)F]DCFPyL PET/CT versus [(18)F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study
por: Oprea-Lager, Daniela-Elena, et al.
Publicado: (2023)

High uptake of (68)Ga-PSMA and (18)F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes
por: Oliveira, Dennis, et al.
Publicado: (2020)

Head-to-Head Comparison of [(18)F]F-choline and Imaging of Prostate-Specific Membrane Antigen, Using [(18)F]DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer
por: García-Zoghby, Laura, et al.
Publicado: (2023)

Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of (18)F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma
por: Mena, Esther, et al.
Publicado: (2022)

Assessment of (18)F-DCFPyL PSMA PET/CT and PET/MR quantitative parameters for reference standard organs: Inter-reader, inter-modality, and inter-patient variability
por: Lawrence, Edward M., et al.
Publicado: (2023)

Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting
por: Johnsson, Kerstin, et al.
Publicado: (2021)

A new automated and putatively versatile synthesis of the PSMA-ligand derivative [(18)F]DCFPyL using the FASTlab(TM) synthesizer
por: Hoareau, Raphaël, et al.
Publicado: (2022)

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT
por: Phillips, Ryan M., et al.
Publicado: (2017)

Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
por: Jansen, B. H. E., et al.
Publicado: (2020)

Comparative study of (18)F-DCFPyL PET/CT and (99m)Tc-MDP SPECT/CT bone imaging for the detection of bone metastases in prostate cancer
por: Hu, Xiongjian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l5mevjkfs4amt2s3eatq5n2kcf